Boston, MA -- (SBWIRE) -- 09/03/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Northstar Realty Finance Corp. (NYSE:NRF), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Alpha Natural Resources, Inc. (NYSE:ANR), Halcon Resources Corp(NYSE:HK)
Northstar Realty Finance Corp. (NYSE:NRF) shares closed at $8.76. The company, on August 16, announced that NorthStar Real Estate Income Trust, Inc., its first sponsored non-traded REIT, successfully priced a $531.5 million non-recourse, floating-rate CMBS transaction at a weighted average coupon of LIBOR + 2.68%. The CMBS transaction will initially be collateralized by $425.2 million of commercial real estate loans with the flexibility to contribute up to $106.3 million of additional commercial real estate loans within six months of closing.
Is NRF A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock jumped 0.94% to $6.41. The company on August 28 announced the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The company plans to initiate a Phase 2 clinical trial for APD811 in the first quarter of 2014. This randomized, double-blind and placebo-controlled Phase 1b clinical trial evaluated the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811. Arena previously evaluated single-ascending doses of APD811 in a Phase 1a clinical trial.
Is ARNA A Good Buy After The Recent Price Movement? Find Out Here
Alpha Natural Resources, Inc. (NYSE:ANR) shares decreased 0.49% to $6.08. The company on August 28 announced topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course. As of end of June data cutoff, 67 AML patients had a minimum follow up of 3 months (50 patients representing the complete cohort of relapsed/refractory AML, and 17 patients in the treatment-naive elderly AML not suitable for induction chemotherapy cohort). The primary endpoint is overall remission rate (Complete Remission or CR; Complete Remission with Incomplete hematologic recovery or CRi/CRp).
How Should Investors Trade ANR After The Recent Volatility? Get Free Report Here
Halcon Resources Corp(NYSE:HK) shares dropped 0.63% to $4.75. The company on August 8 announced that it has priced an underwritten public offering of 38,000,000 shares of its common stock at a price of $5.10 per share. The Company has granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of common stock. The offering is expected to settle and close on August 13, 2013, subject to customary closing conditions.
How Should Investors Trade HK After The Recent Volatility? Get Free Report Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)